A xanthogranulomatous process resembling residual disease on end of-Treatment 18f-FDG-PET/CT and Whole Body Magnetic Resonance performed on a primary breast lymphoma treated by ibrutinib plus rituximab-chop

Antonino Agrusa, Roberto Lagalla, Domenico Albano, Giuseppe Di Buono, Massimo Galia, Eliana Gulotta, Alongi, Caterina Patti, Antonino Mule, Alberto Bruno, Antonino Mule'

Research output: Contribution to journalArticle

Abstract

We report the case of a woman, affected by breast diffuse large B-Cell lymphoma, who developed a xanthogranulomatous process wrongly interpreted as residual disease on 18F-FDG-PET/CTand Whole Body Magnetic Resonance after treatment with ibrutinib plus standard immunochemotherapy. Newer drugs, such as immunomodulatory agents and checkpoint inhibitors, have demonstrated high effectiveness on lymphoma, but are associated with unclear imaging features such as tumor flare or pseudo-progression, related to inflammatory reactions. Wide imaging techniques availability improves diagnostic possibilities. However, the awareness of the adopted treatment strategy and its possible implications on imaging features is crucial to make a correct response assessment.
Original languageEnglish
Pages (from-to)390-395
Number of pages6
JournalGiornale Italiano di Ostetricia e Ginecologia
Volume38
Publication statusPublished - 2016

Fingerprint

Fluorodeoxyglucose F18
Lymphoma
Breast
Magnetic Resonance Spectroscopy
Lymphoma, Large B-Cell, Diffuse
Therapeutics
Pharmaceutical Preparations
Neoplasms
PCI 32765
Rituximab

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynaecology

Cite this

@article{f469f6cf7ee04919ba607e87f2748501,
title = "A xanthogranulomatous process resembling residual disease on end of-Treatment 18f-FDG-PET/CT and Whole Body Magnetic Resonance performed on a primary breast lymphoma treated by ibrutinib plus rituximab-chop",
abstract = "We report the case of a woman, affected by breast diffuse large B-Cell lymphoma, who developed a xanthogranulomatous process wrongly interpreted as residual disease on 18F-FDG-PET/CTand Whole Body Magnetic Resonance after treatment with ibrutinib plus standard immunochemotherapy. Newer drugs, such as immunomodulatory agents and checkpoint inhibitors, have demonstrated high effectiveness on lymphoma, but are associated with unclear imaging features such as tumor flare or pseudo-progression, related to inflammatory reactions. Wide imaging techniques availability improves diagnostic possibilities. However, the awareness of the adopted treatment strategy and its possible implications on imaging features is crucial to make a correct response assessment.",
author = "Antonino Agrusa and Roberto Lagalla and Domenico Albano and {Di Buono}, Giuseppe and Massimo Galia and Eliana Gulotta and Alongi and Caterina Patti and Antonino Mule and Alberto Bruno and Antonino Mule'",
year = "2016",
language = "English",
volume = "38",
pages = "390--395",
journal = "Giornale Italiano di Ostetricia e Ginecologia",
issn = "0391-9013",
publisher = "CIC Edizioni Internazionali s.r.l.",

}

TY - JOUR

T1 - A xanthogranulomatous process resembling residual disease on end of-Treatment 18f-FDG-PET/CT and Whole Body Magnetic Resonance performed on a primary breast lymphoma treated by ibrutinib plus rituximab-chop

AU - Agrusa, Antonino

AU - Lagalla, Roberto

AU - Albano, Domenico

AU - Di Buono, Giuseppe

AU - Galia, Massimo

AU - Gulotta, Eliana

AU - Alongi, null

AU - Patti, Caterina

AU - Mule, Antonino

AU - Bruno, Alberto

AU - Mule', Antonino

PY - 2016

Y1 - 2016

N2 - We report the case of a woman, affected by breast diffuse large B-Cell lymphoma, who developed a xanthogranulomatous process wrongly interpreted as residual disease on 18F-FDG-PET/CTand Whole Body Magnetic Resonance after treatment with ibrutinib plus standard immunochemotherapy. Newer drugs, such as immunomodulatory agents and checkpoint inhibitors, have demonstrated high effectiveness on lymphoma, but are associated with unclear imaging features such as tumor flare or pseudo-progression, related to inflammatory reactions. Wide imaging techniques availability improves diagnostic possibilities. However, the awareness of the adopted treatment strategy and its possible implications on imaging features is crucial to make a correct response assessment.

AB - We report the case of a woman, affected by breast diffuse large B-Cell lymphoma, who developed a xanthogranulomatous process wrongly interpreted as residual disease on 18F-FDG-PET/CTand Whole Body Magnetic Resonance after treatment with ibrutinib plus standard immunochemotherapy. Newer drugs, such as immunomodulatory agents and checkpoint inhibitors, have demonstrated high effectiveness on lymphoma, but are associated with unclear imaging features such as tumor flare or pseudo-progression, related to inflammatory reactions. Wide imaging techniques availability improves diagnostic possibilities. However, the awareness of the adopted treatment strategy and its possible implications on imaging features is crucial to make a correct response assessment.

UR - http://hdl.handle.net/10447/239758

UR - http://www.giog.it/common/php/portiere.php?ID=0b3c9ca6848da671344fcc6e2f4bcfe7

M3 - Article

VL - 38

SP - 390

EP - 395

JO - Giornale Italiano di Ostetricia e Ginecologia

JF - Giornale Italiano di Ostetricia e Ginecologia

SN - 0391-9013

ER -